Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Disease Progression
Disease-Free Survival
Drug Resistance, Neoplasm
/ genetics
Female
Follow-Up Studies
High-Throughput Nucleotide Sequencing
Humans
Immunologic Factors
/ pharmacology
Longitudinal Studies
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Neoplasm Recurrence, Local
/ epidemiology
Prospective Studies
Proteasome Inhibitors
/ pharmacology
Risk Assessment
/ methods
Time Factors
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
11
03
2020
revised:
29
05
2020
accepted:
30
06
2020
pubmed:
4
7
2020
medline:
15
12
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
Duration of first remission is important for the survival of patients with multiple myeloma. From the CoMMpass study (NCT01454297), 926 patients with newly diagnosed multiple myeloma, characterized by next-generation sequencing, were analyzed to evaluate those who experienced early progressive disease (PD; time to progression, TTP ≤18 months). After a median follow-up of 39 months, early PD was detected in 191/926 (20.6%) patients, 228/926 (24.6%) patients had late PD (TTP >18 months), while 507/926 (54.8%) did not have PD at the current follow-up. Compared with patients with late PD, patients with early PD had a lower at least very good partial response rate (47% vs. 82%, Early PD identifies a high-risk multiple myeloma population. Further research is needed to better identify baseline features predicting early PD and the optimal treatment approaches for patients at risk.
Identifiants
pubmed: 32616499
pii: 1078-0432.CCR-20-0951
doi: 10.1158/1078-0432.CCR-20-0951
doi:
Substances chimiques
Immunologic Factors
0
Proteasome Inhibitors
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4832-4841Informations de copyright
©2020 American Association for Cancer Research.